Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 18/20 | 0.57 |
| ▸ | HSD17B1 | P14061 | 12/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247112 | 0.94 | HSD17B2 (0.49) | HSD17B2HSD17B1HDAC6MCHR1 | |
| SCHEMBL2254228 | 0.94 | HSD17B2 (0.49) | HSD17B2HSD17B1HDAC6MCHR1 | |
| SCHEMBL2247439 | 0.92 | HSD17B2 (0.43) | HSD17B2HSD17B1HDAC6 | |
| SCHEMBL2247405 | 0.87 | ACKR3 (0.42) | HSD17B2HSD17B1HDAC6 | |
| SCHEMBL2244955 | 0.86 | HSD17B2 (0.45) | HSD17B2HSD17B1 | |
| SCHEMBL27708405 | 0.86 | IKBKB (0.41) | HSD17B2HSD17B1MCHR1 | |
| SCHEMBL2247408 | 0.86 | ACKR3 (0.41) | HSD17B2HSD17B1HDAC6 | |
| SCHEMBL2249788 | 0.86 | IKBKB (0.39) | HSD17B2HSD17B1 | |
| SCHEMBL2244933 | 0.85 | HSD17B2 (0.51) | HSD17B2 | |
| SCHEMBL2243888 | 0.84 | MKNK1 (0.43) | HSD17B2HSD17B1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | claimed |
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | HSD17B2 2502/4885HSD17B1 2139/4885HDAC6 139/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | HSD17B2 2502/4885HSD17B1 2139/4885HDAC6 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.